Gut Dysbiosis Fractures Into Two Distinct States Tied to Inflammation and Transit Speed
Large-scale genetic analysis of 4,500 microbiomes suggests that gut dysbiosis is divided into contrasting inflammatory and slow-transit profiles.
A sweeping genetic analysis of 4,500 human gut microbiomes reveals that gut dysbiosis, long treated as a single catch-all term for an unbalanced microbiome, actually fractures into at least two distinct biological states linked to gut inflammation and bowel transit speed.
The research, published in eGastroenterology, focused on a specific microbial community profile known as the Bacteroides 2 enterotype, or Bact2. Scientists have long associated this enterotype with low microbial diversity, reduced levels of beneficial bacteria, and chronic inflammation. However, the new work demonstrates that this dysbiotic label masks deep internal variation rather than representing a uniform state across different patients.
How the Human Gut Microbiome Breaks Down Into Different Dysbiosis Profiles
To untangle how gut bacteria vary across health and disease, a team of researchers combined 4,500 faecal microbiome samples from five distinct European cohorts. These groups included healthy volunteers from the Flemish Gut Flora Project alongside patients diagnosed with inflammatory bowel disease, irritable bowel syndrome, multiple sclerosis, and colorectal cancer progression.

Using advanced clustering models to examine the 754 samples classified as the Bact2 enterotype, the investigators mapped how microbial composition relates to clinical and physiological markers. Rather than clustering tightly together, the Bact2 samples separated into three distinct regions. Two of these areas displayed clear biological signatures tied to specific host characteristics, while the third overlapped more closely with healthy, eubiotic microbiome configurations.
What Drives the Inflammatory Subtype of Gut Dysbiosis
The first major subgroup identified in the study is an inflammatory area linked heavily with active inflammatory bowel disease, particularly Crohn’s disease. Patients in this group exhibited high levels of faecal calprotectin, a protein marker indicating intestinal inflammation, alongside elevated C-reactive protein in the blood.
Taxonomically, this inflammatory profile showed severe ecological disruption. It featured the lowest microbial richness and diversity across the entire dataset, accompanied by a marked depletion of beneficial commensal bacteria such as Faecalibacterium. At the same time, opportunistic bacterial genera including Pseudocitrobacter, Streptococcus, and Enterocloster expanded significantly. The authors noted that recent antibiotic use also concentrated within this heavily perturbed group.

Why Slow Transit and Constipation Create a Completely Different Bacterial Balance
In contrast, the second major subgroup revealed a surprising twist regarding bowel transit speed. While classic dysbiosis is frequently associated with faster transit and watery stools, this newly defined slow-transit area correlated with low stool moisture below 65 percent and was more common in older adults.
This slow-transit group maintained higher microbial richness than the inflammatory subgroup and showed distinct elevations in slow-growing bacterial genera such as Alistipes, Oscillibacter, and Flavonifractor. Furthermore, individuals taking thyroid medication, which is frequently linked to constipation, were strongly represented in this configuration. Despite these differences, all Bact2 subgroups maintained higher overall dysbiosis scores and lower bacterial loads than healthy eubiotic enterotypes.

What These Findings Mean for Future Diagnostics and Therapeutics
The authors point out that these findings highlight why interpreting microbiome data can be challenging when dysbiosis is treated as a blunt instrument. Because different underlying drivers such as chronic inflammation or sluggish bowel transit produce distinct microbial shifts, clinicians may need more granular diagnostic frameworks.
However, the researchers emphasize that because the study relies on cross-sectional observational data, it cannot prove direct cause and effect between specific host factors and bacterial shifts. Future longitudinal studies and standardized clinical trials will be necessary to determine whether these microbial configurations represent stable endpoints or dynamic states along a shared disease trajectory.
The research was published in eGastroenterology on November 13, 2026.
This article has been fact checked for accuracy, with information verified against reputable sources. Learn more about us and our editorial process.
Last reviewed on .
Article history
- Latest version
Reference(s)
- Daryoush, Tanine., et al. “Microbiome variation across the intestinal dysbiosis landscape is linked to inflammation and transit time.” eGastroenterology, vol. 4, no. 4, November 13, 2026, pp. e100362 BMJ, doi: 10.1136/egastro-2026-100362. <https://doi.org/10.1136/egastro-2026-100362>.
Cite this page:
- Posted by Elizabeth Taylor